Clinical Trial Update: An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This completed open-label Phase 1/2 trial evaluated the combination of Itacitinib and Osimertinib in subjects with non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Itacitinib (itacitinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED